Jama M Darling
Overview
Explore the profile of Jama M Darling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
334
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McCrary L, Roberts K, Bowman M, Castillo B, Darling J, Dunn C, et al.
J Gen Intern Med
. 2023 Aug;
38(15):3428-3433.
PMID: 37653211
Background: With hepatitis C (HCV) incidence rising due to injection drug use, people who inject drugs (PWID) are a priority population for direct-acting antivirals (DAA). However, significant barriers exist. At...
2.
Sulkowski M, Moon J, Sherman K, Morelli G, Darling J, Muir A, et al.
Hepatology
. 2021 Jul;
74(6):2952-2964.
PMID: 34255381
Background And Aims: Multiple direct-acting antiviral (DAA) regimens are available to treat HCV genotype 1 infection. However, comparative effectiveness from randomized controlled trials of DAA regimens is unavailable. Approach And...
3.
Giang J, Harrison D, Hansen B, Fried M, Darling J
Clin Liver Dis (Hoboken)
. 2021 Jun;
17(5):371-374.
PMID: 34136144
No abstract available.
4.
Harrison D, Giang J, Darling J
Clin Liver Dis (Hoboken)
. 2020 Feb;
15(1):17-20.
PMID: 32104572
No abstract available.
5.
Radhakrishnan K, Di Bisceglie A, Reddy K, Lim J, Levitsky J, Hassan M, et al.
Hepatol Commun
. 2019 Oct;
3(10):1388-1399.
PMID: 31592494
Recent studies have suggested a negative impact of hepatocellular carcinoma (HCC) on sustained virologic response (SVR) to hepatitis C virus (HCV) direct acting antivirals (DAAs). We compared the effectiveness of...
6.
Kimani M, Darling J, Barritt 4th A
J Clin Gastroenterol
. 2016 Apr;
50(6):524.
PMID: 27035077
No abstract available.
7.
Sulkowski M, Vargas H, Di Bisceglie A, Kuo A, Reddy K, Lim J, et al.
Gastroenterology
. 2015 Oct;
150(2):419-29.
PMID: 26497081
Background & Aims: The interferon-free regimen of simeprevir plus sofosbuvir was recommended by professional guidelines for certain patients with hepatitis C virus (HCV) genotype 1 infection based on the findings...
8.
Humphries K, Darling J, Barritt 4th A
Dig Dis Sci
. 2014 Mar;
59(8):2007-12.
PMID: 24633573
No abstract available.
9.
Lawitz E, Lalezari J, Hassanein T, Kowdley K, Poordad F, Sheikh A, et al.
Lancet Infect Dis
. 2013 Mar;
13(5):401-8.
PMID: 23499158
Background: Protease inhibitors have improved treatment of infection with hepatitis C virus (HCV), but dosing, a low barrier to resistance, drug interactions, and side-effects restrict their use. We assessed the...
10.
Barritt 4th A, Darling J, Hayashi P
Curr Hepat Rep
. 2012 Mar;
10(3):179-185.
PMID: 22448143
Hepatitis-C induced liver failure is the leading indication for liver transplantation in the United States, and the burden of hepatitis C virus (HCV)-induced liver disease is not expected to peak...